ASTRAZENECA PLC-SPONS ADR (AZN) Stock Fundamental Analysis

NYSE:AZN • US0463531089

204.52 USD
-0.24 (-0.12%)
At close: Feb 12, 2026
204.66 USD
+0.14 (+0.07%)
Pre-Market: 2/13/2026, 4:44:56 AM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to AZN. AZN was compared to 191 industry peers in the Pharmaceuticals industry. AZN has an excellent profitability rating, but there are some minor concerns on its financial health. AZN has a correct valuation and a medium growth rate. AZN also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year AZN was profitable.
  • In the past year AZN had a positive cash flow from operations.
  • Each year in the past 5 years AZN has been profitable.
  • Each year in the past 5 years AZN had a positive operating cash flow.
AZN Yearly Net Income VS EBIT VS OCF VS FCFAZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • The Return On Assets of AZN (8.96%) is better than 90.58% of its industry peers.
  • AZN has a better Return On Equity (21.01%) than 90.58% of its industry peers.
  • The Return On Invested Capital of AZN (13.63%) is better than 93.72% of its industry peers.
  • AZN had an Average Return On Invested Capital over the past 3 years of 12.48%. This is in line with the industry average of 12.66%.
  • The last Return On Invested Capital (13.63%) for AZN is above the 3 year average (12.48%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROIC 13.63%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
AZN Yearly ROA, ROE, ROICAZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • AZN has a Profit Margin of 17.41%. This is amongst the best in the industry. AZN outperforms 89.01% of its industry peers.
  • AZN's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 23.86%, AZN belongs to the best of the industry, outperforming 91.10% of the companies in the same industry.
  • In the last couple of years the Operating Margin of AZN has grown nicely.
  • The Gross Margin of AZN (81.31%) is better than 85.34% of its industry peers.
  • In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
Industry RankSector Rank
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
AZN Yearly Profit, Operating, Gross MarginsAZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AZN is creating some value.
  • AZN has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for AZN has been increased compared to 5 years ago.
  • AZN has a better debt/assets ratio than last year.
AZN Yearly Shares OutstandingAZN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
AZN Yearly Total Debt VS Total AssetsAZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 3.97 indicates that AZN is not in any danger for bankruptcy at the moment.
  • AZN has a Altman-Z score of 3.97. This is in the better half of the industry: AZN outperforms 69.63% of its industry peers.
  • The Debt to FCF ratio of AZN is 3.42, which is a good value as it means it would take AZN, 3.42 years of fcf income to pay off all of its debts.
  • AZN has a better Debt to FCF ratio (3.42) than 87.96% of its industry peers.
  • AZN has a Debt/Equity ratio of 0.55. This is a neutral value indicating AZN is somewhat dependend on debt financing.
  • The Debt to Equity ratio of AZN (0.55) is worse than 64.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Altman-Z 3.97
ROIC/WACC1.5
WACC9.09%
AZN Yearly LT Debt VS Equity VS FCFAZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.3 Liquidity

  • A Current Ratio of 0.94 indicates that AZN may have some problems paying its short term obligations.
  • With a Current ratio value of 0.94, AZN is not doing good in the industry: 86.91% of the companies in the same industry are doing better.
  • AZN has a Quick Ratio of 0.94. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • AZN has a Quick ratio of 0.72. This is amonst the worse of the industry: AZN underperforms 84.82% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.72
AZN Yearly Current Assets VS Current LiabilitesAZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

5

3. Growth

3.1 Past

  • AZN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.34%.
  • Measured over the past years, AZN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.04% on average per year.
  • The Revenue has grown by 8.63% in the past year. This is quite good.
  • AZN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.15% yearly.
EPS 1Y (TTM)-1.34%
EPS 3Y6.74%
EPS 5Y15.04%
EPS Q2Q%-49.28%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%

3.2 Future

  • AZN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.20% yearly.
  • The Revenue is expected to grow by 6.82% on average over the next years.
EPS Next Y30.41%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
EPS Next 5Y15.2%
Revenue Next Year6.06%
Revenue Next 2Y5.93%
Revenue Next 3Y6.22%
Revenue Next 5Y6.82%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AZN Yearly Revenue VS EstimatesAZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
AZN Yearly EPS VS EstimatesAZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

6

4. Valuation

4.1 Price/Earnings Ratio

  • AZN is valuated quite expensively with a Price/Earnings ratio of 25.03.
  • AZN's Price/Earnings ratio is a bit cheaper when compared to the industry. AZN is cheaper than 78.53% of the companies in the same industry.
  • AZN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 19.20 indicates a rather expensive valuation of AZN.
  • AZN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AZN is cheaper than 79.06% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.69, AZN is valued a bit cheaper.
Industry RankSector Rank
PE 25.03
Fwd PE 19.2
AZN Price Earnings VS Forward Price EarningsAZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • AZN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AZN is cheaper than 82.20% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, AZN is valued a bit cheaper than the industry average as 79.58% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 36.57
EV/EBITDA 17.23
AZN Per share dataAZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • AZN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AZN has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as AZN's earnings are expected to grow with 17.63% in the coming years.
PEG (NY)0.82
PEG (5Y)1.66
EPS Next 2Y20.69%
EPS Next 3Y17.63%

7

5. Dividend

5.1 Amount

  • AZN has a Yearly Dividend Yield of 1.64%. Purely for dividend investing, there may be better candidates out there.
  • AZN's Dividend Yield is rather good when compared to the industry average which is at 0.93. AZN pays more dividend than 91.62% of the companies in the same industry.
  • AZN's Dividend Yield is comparable with the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 1.64%

5.2 History

  • The dividend of AZN has a limited annual growth rate of 3.33%.
  • AZN has paid a dividend for at least 10 years, which is a reliable track record.
  • AZN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.33%
Div Incr Years1
Div Non Decr Years11
AZN Yearly Dividends per shareAZN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • 48.62% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
  • The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.62%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
AZN Yearly Income VS Free CF VS DividendAZN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B
AZN Dividend Payout.AZN Dividend Payout, showing the Payout Ratio.AZN Dividend Payout.PayoutRetained Earnings

ASTRAZENECA PLC-SPONS ADR

NYSE:AZN (2/12/2026, 8:04:00 PM)

Premarket: 204.66 +0.14 (+0.07%)

204.52

-0.24 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10
Earnings (Next)04-29
Inst Owners49.17%
Inst Owner Change0.59%
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap317.06B
Revenue(TTM)58.74B
Net Income(TTM)10.22B
Analysts82.94
Price Target202.76 (-0.86%)
Short Float %0.41%
Short Ratio1.8
Dividend
Industry RankSector Rank
Dividend Yield 1.64%
Yearly Dividend3.21
Dividend Growth(5Y)3.33%
DP48.62%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-25.37%
Min EPS beat(2)-60.38%
Max EPS beat(2)9.64%
EPS beat(4)2
Avg EPS beat(4)-12.23%
Min EPS beat(4)-60.38%
Max EPS beat(4)9.64%
EPS beat(8)4
Avg EPS beat(8)-5.74%
EPS beat(12)7
Avg EPS beat(12)-2.63%
EPS beat(16)11
Avg EPS beat(16)-0.36%
Revenue beat(2)1
Avg Revenue beat(2)-1.31%
Min Revenue beat(2)-4.83%
Max Revenue beat(2)2.2%
Revenue beat(4)1
Avg Revenue beat(4)-2.92%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)2.2%
Revenue beat(8)4
Avg Revenue beat(8)-0.54%
Revenue beat(12)5
Avg Revenue beat(12)-0.86%
Revenue beat(16)6
Avg Revenue beat(16)-0.78%
PT rev (1m)108.28%
PT rev (3m)121.45%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)-0.46%
EPS NY rev (1m)2.29%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE 25.03
Fwd PE 19.2
P/S 5.4
P/FCF 36.57
P/OCF 21.75
P/B 6.51
P/tB N/A
EV/EBITDA 17.23
EPS(TTM)8.17
EY3.99%
EPS(NY)10.65
Fwd EY5.21%
FCF(TTM)5.59
FCFY2.73%
OCF(TTM)9.4
OCFY4.6%
SpS37.89
BVpS31.39
TBVpS-6.72
PEG (NY)0.82
PEG (5Y)1.66
Graham Number75.97
Profitability
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROCE 16.8%
ROIC 13.63%
ROICexc 14.63%
ROICexgc 59.47%
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
FCFM 14.76%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ROICexc(3y)13.49%
ROICexc(5y)11.39%
ROICexgc(3y)81.92%
ROICexgc(5y)83.55%
ROCE(3y)15.36%
ROCE(5y)12.92%
ROICexgc growth 3Y-25.55%
ROICexgc growth 5Y0.81%
ROICexc growth 3Y9.13%
ROICexc growth 5Y9.72%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Debt/EBITDA 1.36
Cap/Depr 103%
Cap/Sales 10.05%
Interest Coverage 10.65
Cash Conversion 73.79%
Profit Quality 84.79%
Current Ratio 0.94
Quick Ratio 0.72
Altman-Z 3.97
F-Score7
WACC9.09%
ROIC/WACC1.5
Cap/Depr(3y)80.57%
Cap/Depr(5y)64.46%
Cap/Sales(3y)8.93%
Cap/Sales(5y)7.69%
Profit Quality(3y)99.49%
Profit Quality(5y)775.68%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.34%
EPS 3Y6.74%
EPS 5Y15.04%
EPS Q2Q%-49.28%
EPS Next Y30.41%
EPS Next 2Y20.69%
EPS Next 3Y17.63%
EPS Next 5Y15.2%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
Revenue Next Year6.06%
Revenue Next 2Y5.93%
Revenue Next 3Y6.22%
Revenue Next 5Y6.82%
EBIT growth 1Y10.05%
EBIT growth 3Y16.67%
EBIT growth 5Y26.09%
EBIT Next Year23.4%
EBIT Next 3Y12.45%
EBIT Next 5Y11.39%
FCF growth 1Y19.18%
FCF growth 3Y6.21%
FCF growth 5Y31.64%
OCF growth 1Y22.88%
OCF growth 3Y14.12%
OCF growth 5Y24.88%

ASTRAZENECA PLC-SPONS ADR / AZN FAQ

Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?

ChartMill assigns a fundamental rating of 6 / 10 to AZN.


What is the valuation status for AZN stock?

ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.


How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?

ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for AZN stock?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 25.03 and the Price/Book (PB) ratio is 6.51.


What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?

The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 30.41% in the next year.